Antiviral Treatment on Pregnancy with COVID-19 Infection : A Systematic Review

Tigor Peniel Simanjuntak, Angela Putri Kakerissa, Grady Ivan Kurniawan


Objective to evaluate antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Method: a systematic review of antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Systematic review was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement.  Result 948 papers accessed through Pubmed, Scopus, Science Direct, Cohcrane, and other with keywords “Antiviral”, “Pregnancy” “Pregnant” “Coronavirus” “COVID-19” “SARS-CoV-2”. Duplicate papers were excluded (n=302),  topics and abstracts that do not meet the criteria (n=612), and 25 papers that did not meet the inclusion criteria. 9 papers that meet the inclusion criteria (case reports and cohort retrospective case study) discussed 20 pregnant women with COVID-19 infection (16 moderate and severe cases received Remdesivir, 3 moderate and mild cases received Lopinavir-ritonavir combination, and 1 moderate case received Arbidol). Conclusion, remdesivir is an antiviral frequently used in pregnancy on trimester II and III with severe COVID-19 infection with a duration of treatment of 5-10 days. Remdesivir should be monitored because some show side effects of increasing liver function.

Pengobatan Ibu Hamil yang Terinfeksi  COVID−19 dengan Antivirus

Tujuan untuk mengevaluasi penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan derajat keparahan. Metode tinjauan literatur sistematis tentang penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan tingkat keparahan. Tinjauan sistematis mengikuti pedoman dari Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Hasil terdapat 948 jurnal yang diakses melalui Pubmed, Scopus, Science Direct, Cohcrane dan lainya dengan kata kunci : Antiviral, Pregnancy, Pregnant, Coronavirus, COVID-19, SARS-CoV-2. Terdapat jurnal yang terduplikasi (n=302), topik dan abstrak yang tidak sesuai kriteria (n=612), dan 25 jurnal yang tidak sesuai kriteria inklusi. Terdapat 9 jurnal yang memenuhi kriteria inklusi (laporan kasus dan studi retrosepktif kohort) yang membahas 20 wanita hamil dengan infeksi COVID-19 (16 kasus dengan derajat sedang dan berat menerima Remdesivir, 3 kasus derajat sedang dan ringan menerima kombinasi Lopinavir-ritonavir, dan 1 kasus derajat sedang menerima Arbidol). Kesimpulan, remdesivir adalah antivirus yang sering digunakan pada wanita hamil trisemester II dan III dengan infeksi COVID-19 derajat berat, lama pengobatan 5-10 hari. Remdesivir harus diwaspadai karena dapat menimbulkan efek samping seperti peningkatan fungsi hati.

Kata kunci: Antivirus, Hamil, COVID-19


Antiviral, pregnant, covid-19

Full Text:



Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Design, Development and Therapy. 2020;Volume 14:3001-3013. (1)

Cavalcante M, Cavalcante C, Braga A, Andrade D, Montenegro M, Santos P et al. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe und Frauenheilkunde. 2021;81(01):46-60.

Wu D, Fang D, Wang R, Deng D, Liao S. Management of Pregnancy during the COVID‐19 Pandemic. Global Challenges. 2020;5(2):2000052.

Anderson J, Schauer J, Bryant S, Graves CR. The use of CONVALESCENT plasma therapy and remdesivir in the successful management of a critically ILL obstetric patient with novel Coronavirus 2019 Infection: A case report. Case Reports in Women's Health. 2020;27.

Akpinar G, Tastan C. The Overall Consequence of Antiviral Drugs Given to Pregnant Women with COVID-19. J Bacteriolv Parasitol. 2021. S10: 002.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 STATEMENT: An UPDATED guideline for reporting systematic reviews. BMJ. 2021;

Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine. 2018;23(2):60–3.

Halscott T and Vaught J. Management considerations for pregnant patients with COVID-19. Society of Maternal and Fetal Medicine, 2020

Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick R. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). Obstetrics & Gynecology. 2020;136(5):1025-1029.

McCoy J, Short W, Srinivas S, Levine L, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. American Journal of Obstetrics & Gynecology MFM. 2020;2(3):100164.

Igbinosa I, Miller S, Bianco K, Nelson J, Kappagoda S, Blackburn B et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. American Journal of Obstetrics and Gynecology. 2020;223(5):768-770.

Dande R, Qureshi A, Persaud K, Puri C, Zulfiqar S, Awasthi S. Remdesivir in a pregnant patient with COVID-19 pneumonia. Journal of Community Hospital Internal Medicine Perspectives. 2021;11(1):103-106.

Saroyo Y, Rumondang A, Febriana I, Harzif A, Irwinda R. Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report. Infectious Disease Reports. 2021;13(2):437-443.

Maldarelli G, Savage M, Mazur S, Oxford-Horrey C, Salvatore M, Marks K. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open Forum Infectious Diseases. 2020;7(9)

Jacobson J, Antony K, Beninati M, Alward W, Hoppe K. Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. Case Reports in Women's Health. 2021;29:e00273.

Ogamba I, Chuang L, Panarelli E, Zilberman D. A case report of COVID-19 infection and management during pregnancy. SAGE Open Medical Case Reports. 2021;9:2050313X2110158.

Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery. Clinical Infectious Diseases. 2020;71(15):844-846.

Castro P, Matos A, Werner H, Lopes F, Tonni G, Araujo Júnior E. Covid-19 and Pregnancy: An Overview. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics. 2020;42(07):420-426.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule gs-5734 against ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5.)

Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine. 2019;381(24):2293–303)

Assessment report - European Medicines Agency [Internet]. [cited 2021Sep12]. Available from:

FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—The Science of Safety and Effectiveness)

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe covid-19. New England Journal of Medicine. 2020;382(24):2327–36.)

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — final report. New England Journal of Medicine. 2020;383(19):1813–26.)

Bertolini A, Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, et al. Abnormal liver function tests in patients with covid‐19 : Relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–72).

Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital With Covid-19 (RECOVERY): A RANDOMISED, CONTROLLED, OPEN-LABEL, Platform trial. The Lancet. 2020;396(10259):1345–52.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. New England Journal of Medicine. 2020;382(19):1787–99.

(Kim A and Gandhi R. Coronavirus disease 2019 (COVID-19): management in hospitalized adults. Waltham, MA: Uptodate, 2020.)

(Taylor M, Kobeissi L, Kim C, Amin A, Thorson A, Bellare N et al. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. The Lancet Global Health. 2021;9(3):e366-e371.)

(Mei Y, Luo D, Wei S, Liao X, Pan Y, Yang X et al. Obstetric Management of COVID-19 in Pregnant Women. Frontiers in Microbiology. 2020;11.).

Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on covid-19: A randomized controlled trial. BMC Infectious Diseases. 2020;20(1).

Lu D, Sang L, Du S, Li T, Chang Y, Yang XA. Asymptomatic COVID‐19 infection in late pregnancy indicated no vertical transmission. Journal of Medical Virology. 2020;92(9):1660–4.



  • There are currently no refbacks.


Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
  Web Analytics
  View My Stat